FIT

(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-tert-butyl-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide

Find entries where: FIT

is present as a standalone ligand in 1 entries

Find related ligands:

Chemical Component Summary
Name	(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-tert-butyl-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Synonyms	FINASTERIDE
Identifiers	(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
Formula	C₂₃ H₃₆ N₂ O₂
Molecular Weight	372.544
Type	NON-POLYMER
Isomeric SMILES	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C
InChI	InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1
InChIKey	DBEPLOCGEIEOCV-WSBQPABSSA-N

Chemical Details
Formal Charge	0
Atom Count	63
Chiral Atom Count	7
Bond Count	66
Aromatic Bond Count	0

Drug Info: DrugBank

DrugBank ID	DB01216
Name	Finasteride
Groups	approved
Description	Finasteride is a synthetic 4-azasteroid compound [L10565] and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an orally active drug that was first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and reduce the risk for acute urinary retention or the need for surgical procedures.[L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss.[L6244] Finasteride is commonly marketed under the brand names Propecia and Proscar to be used aloneo or in combination with [doxazosin], an alpha-blocker. Both benign prostatic hyperplasia and androgenic alopecia are androgen-dependent disorders that are characterized by _in situ_ high levels of DHT.[A178159] In the treatment of benign prostate hyperplasia, alpha-blockers such as [tamsulosin] and [terazosin] are also used. Compared to alpha-blockers that focus on providing the rapid relief of symptoms, 5α-reductase inhibitors aim to target the underlying disease by blocking the effects of the primary androgen involved in benign prostate hyperplasia and androgenic alopecia, thus reducing the risk for secondary complications while providing symptom control.[A2132]
Synonyms	Finasterida (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide Finasteride Finasteridum
Brand Names	Ntp-finasteride PMS-finasteride Jamp-finasteride Act Finasteride Bio-finasteride Van-finasteride Sandoz Finasteride Nra-finasteride M-finasteride Proscar Accel-finasteride Tablets USP Dexamethasone Sodium Phosphate 0.1% / Finasteride 0.1% / Minoxidil 5% / Tretinoin 0.025% Teva-finasteride Ran-finasteride Ach-finasteride Finasteride 0.1% / Minoxidil 5% Mint-finasteride Mylan-finasteride Mylan-finasteride Hg Finasteride Apo-finasteride Ratio-finasteride Auro-finasteride 1mg Ag-finasteride Propecia Dom-finasteride Finasteride 0.1% / Minoxidil 7% / Tretinoin 0.025% Entadfi Auro-finasteride Riva-finasteride Sandoz Finasteride A Dexamethasone Sodium Phosphate 0.1% / Finasteride 0.1% / Minoxidil 5% Finasteride 0.1% / Minoxidil 7%
Indication	Finasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy.[L10565] A combination product with [tadalafil] is also used for the symptomatic treatment of BPH for up to 26 weeks.[L39439] Finasteride is also indicated for the treatment of male pattern hair loss (androgenetic alopecia, hereditary alopecia, or common male baldness) in male patients.[L6235]
Categories	5-alpha Reductase Inhibitors Adrenergic alpha-Antagonists Adrenergic Antagonists Agents that produce hypertension Androstanes Androstenes Azasteroids Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 CYP3A5 Substrates Cytochrome P-450 CYP3A7 Substrates Cytochrome P-450 Substrates Dermatologicals Drugs Used in Benign Prostatic Hypertrophy Enzyme Inhibitors Fused-Ring Compounds Genito Urinary System and Sex Hormones Genitourinary Agents Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Misc. Skin and Mucous Membrane Agents Steroid Synthesis Inhibitors Steroids Urological Agents Urologicals
ATC-Code	D11AX10 G04CA55 G04CA51 G04CB51 G04CB01
CAS number	98319-26-7

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
3-oxo-5-alpha-steroid 4-dehydrogenase 2	MQVQCQQSPVLAGSATLVALGALALYVAKPSGYGKHTESLKPAATRLPAR...	unknown	inhibitor
3-oxo-5-alpha-steroid 4-dehydrogenase 1	MATATGVAEERLLAALAYLQCAVGCAVFARNRQTNSVYGRHALPSHRLRV...	unknown	inhibitor
3-oxo-5-beta-steroid 4-dehydrogenase	MDLSAASHRIPLSDGNSIPIIGLGTYSEPKSTPKGACATSVKVAIDTGYR...	unknown	inhibitor
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate
Cytochrome P450 3A5	MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...	unknown	substrate
Cytochrome P450 3A7	MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNA...	unknown	substrate
Solute carrier family 12 member 5	MSRRFTVTSLPPAASAASADPESRRHSVADPRRLPREDVKGDGNPKESSP...	unknown	modulator
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682